Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

NCT07388771 · tracked via the Priya Life Science China tracker

Sponsor

Qian Chu

Phase

Observational

Started

2025-12-01

Last updated

2026-03-19

Condition(s) studied

NSCLCNeoadjuvant Therapy

Study summary

This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.

The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent or metastatic lung cancer; 2. patients with other primary tumors

Primary outcome measure(s)

pathologic response — Perioperative

Trial sites (2)

Facility	City	Region	Status
Tongji hospital	Wuhan	Hubei	Recruiting
Sir Run Run Shaw Hospital	Hangzhou	Zhejiang	Recruiting

More Qian Chu trials in China

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative Recruiting

Durvalumab as Consolidation for Patients LS-SCLC Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma Recruiting

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes Recruiting

Other trials for the same condition

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer Recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases Recruiting

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer Recruiting

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388771 on ClinicalTrials.gov ↗ ← All trials in China